Literature DB >> 3323505

Cyclosporine treatment of steroid resistant interstitial pneumonitis associated with dermatomyositis/polymyositis.

W B Gruhn1, J A Diaz-Buxo.   

Abstract

We report the successful treatment with cyclosporine of a patient with steroid resistant interstitial pneumonitis associated with polymyositis and review the literature regarding the use of cyclosporine in the treatment of interstitial lung disease.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3323505

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


  6 in total

Review 1.  Recognition and management of myositis.

Authors:  P Cherin
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

2.  The long-term outcome of anti-Jo-1-positive inflammatory myopathies.

Authors:  Michael Späth; Mira Schröder; Beate Schlotter-Weigel; Maggie C Walter; Hubert Hautmann; Gerda Leinsinger; Dieter Pongratz; Wolfgang Müller-Felber
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

Review 3.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

4.  Very low-dose cyclosporin treatment of steroid-resistant interstitial pneumonitis associated with Sjögren's syndrome.

Authors:  H Ogasawara; M Sekiya; A Murashima; T Hishikawa; Y Tokano; I Sekigawa; N Iida; H Hashimoto; S Hirose
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

5.  Cyclosporin as a treatment for interstitial lung disease of unknown aetiology.

Authors:  J A Moolman; P G Bardin; D J Rossouw; J R Joubert
Journal:  Thorax       Date:  1991-08       Impact factor: 9.139

6.  Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis.

Authors:  K Kurasawa; Y Nawata; K Takabayashi; K Kumano; Y Kita; Y Takiguchi; T Kuriyama; M Sueishi; Y Saito; I Iwamoto
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.